P. Dahia, Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity, Nature Reviews Cancer, vol.285, issue.2, pp.108-119, 2014.
DOI : 10.1038/nrc3648

J. Crona, M. Nordling, and R. Maharjan, Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours, PLoS ONE, vol.23, issue.1, p.86756, 2014.
DOI : 10.1371/journal.pone.0086756.t004

*. Castro?vega, L. Letouze, E. Burnichon, and N. , Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas, Nature Communications, vol.26, p.6044, 2015.
DOI : 10.1038/ncomms7044

C. Jimenez, E. Rohren, and M. Habra, Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma, R111?122. Review about management and therapeutical options for patients with metastatic PPGL, 2013.

D. Astuti, F. Latif, and A. Dallol, Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma, The American Journal of Human Genetics, vol.69, issue.1, pp.49-54, 2001.
DOI : 10.1086/321282

N. Burnichon, J. Briere, and R. Libe, SDHA is a tumor suppressor gene causing paraganglioma, Human Molecular Genetics, vol.19, issue.15, pp.3011-3020, 2010.
DOI : 10.1093/hmg/ddq206

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901140

H. Hao, O. Khalimonchuk, and M. Schraders, SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma, Science, vol.325, issue.5944, pp.1139-1142, 2009.
DOI : 10.1126/science.1175689

S. Niemann and U. Muller, Mutations in SDHC cause autosomal dominant paraganglioma, type 3, Nat Genet, vol.26, pp.268-270, 2000.

Y. Qin, L. Yao, and E. King, Germline mutations in TMEM127 confer susceptibility to pheochromocytoma, Nature Genetics, vol.24, issue.3, pp.229-233, 2010.
DOI : 10.1038/ng.533

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998199

I. Comino?mendez, F. Gracia?aznarez, and F. Schiavi, Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma, Nature Genetics, vol.8, issue.7, pp.663-667, 2011.
DOI : 10.1677/ERC-09-0016

*. Cascon, A. Comino?mendez, I. Curras?freixes, and M. , Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene, JNCI Journal of the National Cancer Institute, vol.107, issue.5, 2015.
DOI : 10.1093/jnci/djv053

P. Dahia, K. Ross, and M. Wright, A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas, PLoS Genet, vol.1, pp.72-80, 2005.

E. Lopez?jimenez, G. Gomez?lopez, and L. Leandro?garcia, Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas, Molecular Endocrinology, vol.24, issue.12, pp.2382-2391, 2010.
DOI : 10.1210/me.2010-0256

N. Burnichon, L. Vescovo, and L. Amar, Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma, Human Molecular Genetics, vol.20, issue.20, pp.3974-3985, 2011.
DOI : 10.1093/hmg/ddr324

URL : http://hmg.oxfordjournals.org/cgi/content/short/20/20/3974

E. Letouze, C. Martinelli, and C. Loriot, SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma, Cancer Cell, vol.23, issue.6, pp.739-752, 2013.
DOI : 10.1016/j.ccr.2013.04.018

A. De-cubas, L. Leandro?garcia, and F. Schiavi, Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways, Endocrine Related Cancer, vol.20, issue.4, pp.477-493, 2013.
DOI : 10.1530/ERC-12-0183

*. De-cubas, A. Korpershoek, E. Inglada?perez, and L. , DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers, 3020?3030. DNA methylation study in metastatic PPGLs identifying prognostic markers, 2015.
DOI : 10.1158/1078-0432.CCR-14-2804

L. Amar, E. Baudin, and N. Burnichon, Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.10, pp.3822-3828, 2007.
DOI : 10.1210/jc.2007-0709

A. Gimenez?roqueplo, J. Favier, and R. P. , Mutations in the SDHB gene are associated with extra?adrenal and/or malignant phaeochromocytomas, Cancer Res, vol.63, pp.5615-5621, 2003.

B. Pasini and C. Stratakis, SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes, Journal of Internal Medicine, vol.1073, issue.1, pp.19-42, 2009.
DOI : 10.1111/j.1365-2796.2009.02111.x

Z. Zhuang, C. Yang, and F. Lorenzo, Gain-of-Function Mutations in Paraganglioma with Polycythemia, New England Journal of Medicine, vol.367, issue.10, pp.922-930, 2012.
DOI : 10.1056/NEJMoa1205119

L. Castro?vega, A. Buffet, D. Cubas, and A. , Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas, Human Molecular Genetics, vol.23, issue.9, pp.2440-2446, 2014.
DOI : 10.1093/hmg/ddt639

*. Clark, G. Sciacovelli, M. Gaude, and E. , Germline FH mutations presenting with pheochromocytoma, J Clin Endocrinol Metab, vol.99, 2014.

I. Comino?mendez, A. De-cubas, and C. Bernal, Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis, Human Molecular Genetics, vol.22, issue.11, pp.2169-2176, 2013.
DOI : 10.1093/hmg/ddt069

*. Welander, J. Andreasson, A. Brauckhoff, and M. , Frequent EPAS1/HIF2alpha exons 9 and 12 mutations in non?familial pheochromocytoma, Endocr Relat Cancer, vol.21, 2014.

A. Buffet, S. Smati, and L. Mansuy, -Related Polycythemia-Paraganglioma Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.369-373, 2014.
DOI : 10.1210/jc.2013-2600

URL : https://hal.archives-ouvertes.fr/inria-00607403

*. Hadoux, J. Favier, J. Scoazec, and J. , SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma, 2711?2720. Demonstration that temozolomide is an effective treatment in SDHB?related malignant PPGLs, 2014.

N. Burnichon, A. Buffet, and B. Parfait, Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma, Human Molecular Genetics, vol.21, issue.26, pp.5397-5405, 2012.
DOI : 10.1093/hmg/dds374

J. Welander, C. Larsson, and M. Backdahl, Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas, Human Molecular Genetics, vol.21, issue.26, pp.5406-5416, 2012.
DOI : 10.1093/hmg/dds402

URL : http://hmg.oxfordjournals.org/cgi/content/short/21/26/5406

*. Wells, S. , J. Asa, S. Dralle, and H. , Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, Thyroid, vol.25, issue.6, pp.567-610, 2015.
DOI : 10.1089/thy.2014.0335

L. Amar, J. Bertherat, and E. Baudin, Genetic Testing in Pheochromocytoma or Functional Paraganglioma, Journal of Clinical Oncology, vol.23, issue.34, pp.8812-8818, 2005.
DOI : 10.1200/JCO.2005.03.1484

*. Lenders, J. Duh, Q. Eisenhofer, and G. , Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.6, 2014.
DOI : 10.1210/jc.2014-1498

N. Burnichon, A. Cascon, and F. Schiavi, MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma, Clinical Cancer Research, vol.18, issue.10, pp.2828-2837, 2012.
DOI : 10.1158/1078-0432.CCR-12-0160

URL : https://hal.archives-ouvertes.fr/hal-01048691

J. Crona, D. Verdugo, A. Maharjan, and R. , in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.7, pp.1266-1271, 2013.
DOI : 10.1210/jc.2012-4257

*. Luchetti, A. Walsh, D. Rodger, and F. , Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis NGS analysis of 85 PPGL tumour samples for "mutation hotspots, Int J Endocrinol, vol.2015, p.138573, 2015.

*. Curras?freixes, M. Inglada?perez, L. Mancikova, and V. , Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients, sequencing?based genetic testing strategy in PPGLs, 2015.
DOI : 10.1136/jmedgenet-2015-103218

*. Fishbein, L. Khare, S. Wubbenhorst, and B. , Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas, Nature Communications, vol.206, p.6140, 2015.
DOI : 10.1038/ncomms7140

*. Flynn, A. Benn, D. Clifton?bligh, and R. , The genomic landscape of phaeochromocytoma, 78?89. Study of 40 PPGL tumour tissues using RNA?Seq , WES and SNP array, 2015.
DOI : 10.1002/path.4503

*. Juhlin, C. Stenman, A. Haglund, and F. , Whole?exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene, 542?554. Identification of KMT2D mutations in sporadic PPGLs using a WES strategy, 2015.

A. Stenman, C. Juhlin, and F. Haglund, Absence of KMT2D/MLL2 mutations in abdominal paraganglioma, Clin Endocrinol (Oxf), 2015.

*. Papathomas, T. Oudijk, L. Zwarthoff, and E. , Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia, Prevalence of TERT promoter mutations in adrenal tumours and PGL, 2014.
DOI : 10.1530/ERC-13-0429

T. Liu, T. Brown, and C. Juhlin, The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors, Endocrine Related Cancer, vol.21, issue.3, pp.427-434, 2014.
DOI : 10.1530/ERC-14-0016

R. Casey, A. Garrahy, and A. Tuthill, Universal Genetic Screening Uncovers a Novel Presentation of an SDHAF2 Mutation, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.7, pp.1392-1396, 2014.
DOI : 10.1210/jc.2013-4536

J. Crona, A. Verdugo, and D. Granberg, Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma, Endocrine Connections, vol.2, issue.2, pp.104-111, 2013.
DOI : 10.1530/EC-13-0009

E. Rattenberry, L. Vialard, and A. Yeung, A Comprehensive Next Generation Sequencing???Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.7, pp.1248-1256, 2013.
DOI : 10.1210/jc.2013-1319

*. Welander, J. Andreasson, A. Juhlin, and C. , Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.7, pp.1352-1360, 2014.
DOI : 10.1210/jc.2013-4375

*. Toledo, R. Dahia, and P. , Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes, Current Opinion in Endocrinology & Diabetes and Obesity, vol.22, issue.3, pp.169-179, 2015.
DOI : 10.1097/MED.0000000000000150

*. Crona, J. Backman, S. Maharjan, and R. , Spatio?temporal heterogeneity characterizes the genetic landscape of pheochromocytoma and defines early events in tumourigenesis Investigation of 136 PPGL tumour samples demonstrating a genetic heterogeneity between patients, between tumours of one patient and within tumour lesions, Clin Cancer Res FIGURE TITLE AND LEGEND, 2015.